Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies
Summary
HOUSTON, Texas & TUEBINGEN, Germany--(BUSINESS WIRE)--Immatics Biotechnologies GmbH (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced it has entered into a definitive business combination agreement with Arya Sciences Acquisition Corp. (NASDAQ: ARYA) (“Arya”), a special purpose acquisition company, sponsored by Perceptive Advisors. In addition to the funds held in Arya’s trust account, a group of leading US healthcare investors has committed to participate in the transaction through a ~$104 million common stock PIPE. Access to the US capital markets will be critical to our ability to fuel our development plans and to advance Immatics’ innovative immunotherapies through the clinic as part of our mission to improve treatment options for cancer patients.” Immatics leverages advanced technologies and biologic insight to identify otherwise inaccessible and intracellular drug targets as a basis for a broad range of cancer immunotherapies designed to overcome the current limitations in immuno-oncology. Additional information about the transaction will be provided in a Current Report on Form 8-K that will contain an investor presentation to be filed with the Securities and Exchange Commission (“SEC”) and will be available at www.sec.gov. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, anticipated financial impacts of the business combination, the ability of the parties to consummate the proposed business combination and the satisfaction of closing conditions, and Arya’s ability to obtain the financing necessary to consummate the potential transaction.